Cell Therapies Pty Ltd (Cell Therapies), a leading manufacturer and distributor of cellular therapies in the Asia-Pacific region, is pleased to announce significant change to board structure in anticipation of the next stage of corporate growth.
Following successful restructuring of Cell Therapies’ growth strategy and new CEO recruitment, Dr Christian Behrenbruch will step down as a Peter MacCallum Cancer Centre (Peter Mac) nominee director and Chairman of Cell Therapies. Professor James Angus AO will join as a Peter Mac nominee director. Professor Angus was Dean of the Faculty of Medicine, Dentistry and Health Sciences at the University of Melbourne, is a past director of Melbourne Health and is currently a director of Peter Mac. Dr Behrenbruch will continue to serve as a transaction and financing advisor to the Board.
Mr Dennis O’Keeffe has joined the board following the retirement of Mr Daniel Pilbrow, also a Peter Mac nominee director. Mr O’Keeffe is currently Chief Financial Officer at Peter MacCallum Cancer Centre and deepens the financial and operational relationship between the Peter Mac and Cell Therapies.
Finally, Dr Tim Oldham, who was appointed CEO in April 2014, joins the board as Managing Director.
In welcoming Professor Angus and Mr O’Keeffe, Dr Oldham said “our new directors will play an important role ensuring Cell Therapies has a robust foundation from which to execute our growth plan. Our clinical and research linkages with Peter Mac not only provide Peter Mac with the capabilities to deliver cutting edge cellular therapies in oncology and haematology, they also provide significant value-add to our clients and customers. Our move from East Melbourne to new facilities in the heart of Melbourne’s renowned biomedical Parkville precinct in 2016/17 will strengthen linkages and Professor Angus and Mr O’Keeffe will be particularly beneficial in preparing for that transition.
We thank Dr Behrenbruch and Mr Pilbrow for their contribution to Cell Therapies as we have readied ourselves for growth and we are pleased that Dr Behrenbruch will continue to act in an advisory capacity during our capital raising activities.”
About Cell Therapies Pty Ltd:
Cell Therapies is the leading manufacturer and distributor of cellular therapies in Asia Pacific, a region of over 650 million people. Cell Therapies provides the essential manufacturing and distribution infrastructure for the safe, reliable and scalable delivery of cellular therapies into clinical trials and for therapeutic use.
For over a decade, Cell Therapies has made these capabilities available on a contract basis to some of the world’s leading stem cell companies, developing products and processes that are compliant with global regulatory and cGMP requirements and successfully integrating with global manufacturing networks. Cell Therapies also in-licenses late stage products for high unmet clinical need for commercialisation in SE Asia and Australasia.
Partner, investor and media enquiries to:
Dr Tim Oldham
Chief Executive Officer
+61 3 9656 1615